Induced pluripotent stem cells in clinical hematology: potentials, progress, and remaining obstacles.

Current Opinion in Hematology
Athanasia D Panopoulos, Juan C I Belmonte

Abstract

With the advent of reprogramming came the possibility of generating patient-specific clinical therapies. The purpose of this review is to discuss the recent key developments and remaining limitations in the stem cell and hematopoietic fields toward the goal of translating induced pluripotent stem cell (iPSC) technologies into the hematology clinic. Recent progress in the hematopoietic and reprogramming fields has included identification of hematopoietic stem cells (HSCs) capable of long-term engraftment at the single-cell level, improvements in ex-vivo expansion of HSCs, transdifferentiation of somatic cells into hematopoietic progenitors, and the 'correction' of several disease-specific iPSCs using various gene-targeting strategies. In light of recent advances, it is the hope that the hurdle of obtaining fully functional HSCs in a laboratory setting will be overcome through either in-vitro differentiation of pluripotent stem cells, ex-vivo expansion of HSCs obtained in vivo, or transdifferentiation from other somatic sources. Equally important will be for the reprogramming field to better understand the causes and consequences of the recently reported genetic/epigenetic variations present in iPSCs, especially within the contex...Continue Reading

References

Nov 6, 1998·Science·J A ThomsonJ M Jones
Jan 18, 2006·Annual Review of Medicine·Claudio G Brunstein, John E Wagner
Mar 4, 2011·Nature·Samer M HusseinTimo Otonkoski
Mar 26, 2011·Blood·Ann DahlbergIrwin D Bernstein
Apr 6, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sara E HowdenJames A Thomson
Apr 9, 2011·Cell Stem Cell·Athanasia D PanopoulosJuan Carlos Izpisua Belmonte
May 21, 2011·Cell Stem Cell·Guang-Hui LiuJuan Carlos Izpisua Belmonte
Jun 10, 2011·Nature Biotechnology·Kristen Martins-TaylorRen-He Xu
Aug 9, 2011·Stem Cells·Kristen Martins-Taylor, Ren-He Xu
Jan 11, 2012·Nature Biotechnology·Simon Frantz
Jan 20, 2012·Nature·Daisy A Robinton, George Q Daley
Jan 28, 2012·Lancet·Steven D SchwartzRobert Lanza
Feb 7, 2012·Cell Stem Cell·Sergei DoulatovJohn E Dick

❮ Previous
Next ❯

Citations

Nov 30, 2013·BioMed Research International·Teresa de Souza FernandezAndré Luiz Mencalha
Feb 23, 2018·Leukemia·Saloomeh MokhtariGraça Almeida-Porada
Dec 24, 2013·The Journal of Biological Chemistry·Zachary S ScheinerEllen G Feigal
Nov 13, 2013·Expert Review of Clinical Immunology·Anna BerglöfC I Edvard Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.